Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature.
作者信息
Iniesta Arandia Nerea, Espinosa Gerard, Guillén Del Castillo Alfredo, Tolosa-Vilella Carles, Colunga-Argüelles Dolores, González de Echávarri Pérez de Heredia Cristina, Lledó Gema M, Comet Luis Sáez, Ortego-Centeno Norberto, Vargas Hito José Antonio, Rubio-Rivas Manuel, Freire Mayka, Ríos-Blanco Juan José, Rodríguez-Carballeira Mónica, Trapiella-Martínez Luis, Fonollosa-Pla Vicent, Simeón-Aznar Carmen Pilar
机构信息
From the Department of Autoimmune Diseases, Institut Clinic de Medicina i Dermatologia, Hospital Clínic, Barcelona, Catalonia, Spain.
Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Catalonia, Spain.
出版信息
J Clin Rheumatol. 2022 Jan 1;28(1):e180-e188. doi: 10.1097/RHU.0000000000001676.
OBJECTIVES
To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis.
METHODS
From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies.
RESULTS
Seventy-two of 947 patients (7.6%) tested positive for PM/Scl antibodies. Patients with PM/Scl antibodies presented initially with more puffy fingers and arthralgias but less Raynaud phenomenon. Regarding cumulative manifestations, myositis and arthritis were more prevalent in patients with PM/Scl antibodies, as well as pulmonary fibrosis. On the contrary, patients with PM/Scl antibodies had less pulmonary hypertension. No difference in terms of survival at 5 and 10 years was noticed between the 2 groups.
CONCLUSIONS
In systemic sclerosis patients from Spain, PM/Scl antibodies are associated with a distinct clinical profile. However, PM/Scl antibodies did not influence survival.
Zotero 插件